Maxpro Capital Acquisition Corp. (JMAC) to Combine with Apollomics

Maxpro Capital (NASDAQ:JMAC) has entered into a definitive agreement to combine with biopharmaceutical firm Apollomics at a pre-money equity value of $899 million. Foster City, California-based is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets. The combined company is expected
Read More